Synlogic, Inc. (SYBX): History, Ownership, Mission, How It Works & Makes Money

Ever heard of Synlogic, Inc. (SYBX) and wondered what they're all about? This biopharmaceutical company is making waves with its innovative approach to treating serious diseases, but how exactly do they operate and generate revenue? Join us as we delve into Synlogic's history, explore its mission, understand its unique synthetic biotics platform, and analyze its financial performance, including a $23.36 million loss in 2024, a 59.22% decrease compared to 2023.

Synlogic, Inc. (SYBX) History

Synlogic, Inc. Founding Timeline

Year established

Synlogic was founded in 2013.

Original location

The company is headquartered in Cambridge, Massachusetts.

Founding team members

Synlogic was co-founded by James Collins and Timothy Lu, based on research originating from MIT.

Initial capital/funding

In 2014, Synlogic completed a Series A financing round, raising $30 million. This funding was led by Atlas Venture and New Enterprise Associates.

Synlogic, Inc. Evolution Milestones

Synlogic, Inc. Transformative Moments

• Strategic Shift to Focus on Key Programs: Synlogic has undergone strategic realignments to focus resources on its most promising clinical programs, particularly in metabolic disorders and cancer.
• Partnerships and Collaborations: Collaborations with companies like Ginkgo Bioworks and other academic institutions have expanded Synlogic's technological capabilities and pipeline potential.
• Clinical Trial Outcomes: Results from clinical trials, both positive and negative, have significantly influenced the direction of research and development efforts, leading to strategic pivots and program adjustments.
• Financial Decisions: Decisions regarding financing, including IPOs, follow-on offerings, and private placements, have provided the capital necessary to fund operations and advance clinical programs.

For an in-depth look at the company's financial status, check out: Breaking Down Synlogic, Inc. (SYBX) Financial Health: Key Insights for Investors

Synlogic, Inc. (SYBX) Ownership Structure

Synlogic, Inc. has a mixed ownership structure comprising institutional investors, individual shareholders, and company insiders.

Synlogic, Inc. Current Status

Synlogic, Inc. is a public company, trading on the Nasdaq Global Market under the ticker symbol SYBX.

Synlogic, Inc. Ownership Breakdown

Synlogic's ownership is distributed among various shareholders, with institutional investors holding a significant portion. As of the fiscal year 2024, the ownership breakdown is as follows:

Synlogic, Inc. Leadership

Synlogic's leadership team is responsible for guiding the company's strategic direction and overseeing its operations. Key members of the leadership team include:

• Aoife Brennan, M.B. Ch.B., Ph.D., President and Chief Executive Officer
• Gregg Beloff, Chief Financial Officer
• Antoine Awad, M.D., Chief Medical Officer

For more insights into Synlogic's strategic objectives, explore: Mission Statement, Vision, & Core Values of Synlogic, Inc. (SYBX).

Synlogic, Inc. (SYBX) Mission and Values

Synlogic is dedicated to developing synthetic biotic medicines to treat diseases, aiming to transform the lives of patients. The company values innovation, collaboration, and a patient-focused approach in its pursuit of novel therapeutic solutions.

Synlogic's Core Purpose

Official mission statement

Synlogic's mission is to transform the lives of patients by developing synthetic biotic medicines. This involves:

• Pioneering the creation of a novel class of living medicines.
• Addressing unmet medical needs through innovative biological engineering.
• Focusing on diseases where current treatments are inadequate.

Vision statement

Synlogic envisions a future where synthetic biotic medicines are a mainstream therapeutic option, offering significant benefits to patients across a range of diseases. This includes:

• Establishing a leadership position in the field of synthetic biology therapeutics.
• Expanding the application of their technology platform to multiple disease areas.
• Creating value for patients, shareholders, and the broader healthcare community.

Company slogan/tagline

While Synlogic does not have a single, publicly promoted slogan or tagline, their core messaging revolves around:

• 'Synthetic Biotic Medicines for a Healthier Future' – emphasizing their commitment to innovative treatments.
• 'Engineering Biology to Transform Lives' – highlighting their unique approach to drug development.
• 'Pioneering a New Era of Living Medicines' – underscoring their position at the forefront of a novel therapeutic field.

For more insights into Synlogic's financial standing, you might find this resource helpful: Breaking Down Synlogic, Inc. (SYBX) Financial Health: Key Insights for Investors

Synlogic, Inc. (SYBX) How It Works

Synlogic, Inc. operates as a clinical-stage biopharmaceutical company focused on discovering and developing Synthetic Biotic medicines for the treatment of metabolic and inflammatory diseases, and cancer.

Synlogic's Product/Service Portfolio

Synlogic's Operational Framework

Synlogic's operations are centered around the engineering and development of microbial-based therapeutics. Key aspects of their operational framework include:

• Strain Engineering: Utilizing synthetic biology to create microbial strains with specific functionalities.
• Preclinical Development: Conducting in vitro and in vivo studies to assess safety and efficacy.
• Clinical Trials: Progressing drug candidates through Phase 1, Phase 2, and Phase 3 clinical trials to evaluate their impact on patients.
• Manufacturing: Developing scalable manufacturing processes to produce Synthetic Biotic medicines.
• Partnerships: Collaborating with research institutions and other companies to advance their pipeline.

Synlogic's Strategic Advantages

Synlogic's strategic advantages stem from its innovative approach to treating diseases and its unique technology platform:

• Synthetic Biotic Platform: A versatile platform that allows for the rapid design and development of new therapies.
• Focus on Unmet Needs: Targeting diseases with limited treatment options.
• Intellectual Property: A strong patent portfolio protecting its technology and product candidates.
• Experienced Management Team: A team with expertise in synthetic biology, drug development, and commercialization.

To learn more about Synlogic's investors, read this article: Exploring Synlogic, Inc. (SYBX) Investor Profile: Who’s Buying and Why?

Synlogic, Inc. (SYBX) How It Makes Money

Synlogic, Inc. operates as a clinical-stage biopharmaceutical company, primarily focused on discovering and developing synthetic biotic medicines to treat diseases.

Synlogic, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Synlogic, Inc. currently does not generate revenue from product sales. Its revenue primarily consists of collaborative and grant revenue.

Synlogic, Inc.'s Business Economics

Synlogic's business economics are characterized by substantial research and development (R&D) expenses, typical of a biotechnology company in the clinical stage. The company heavily relies on partnerships and collaborations to fund its operations and advance its pipeline.

• R&D Investments: A significant portion of Synlogic's expenditure is allocated to R&D, which includes preclinical studies, clinical trials, and manufacturing process development.
• Partnerships: Strategic alliances with pharmaceutical companies and research institutions provide funding and expertise, which are crucial for advancing Synlogic's programs.
• Grant Funding: Non-dilutive funding through grants helps support specific research projects and reduces the financial burden on the company.

Synlogic, Inc.'s Financial Performance

Synlogic's financial performance reflects its status as a development-stage company. Key aspects include:

• Cash Position: Monitoring cash reserves is vital, as these funds support ongoing R&D and operational activities.
• Operating Expenses: A large portion of expenses is attributed to R&D, alongside general and administrative costs.
• Net Losses: The company typically reports net losses as it invests heavily in its pipeline without generating substantial product revenue.

For an in-depth analysis of Synlogic, Inc.'s financial health, you can explore this resource: Breaking Down Synlogic, Inc. (SYBX) Financial Health: Key Insights for Investors

Synlogic, Inc. (SYBX) Market Position & Future Outlook

Synlogic is strategically positioned to leverage its expertise in synthetic biology to develop novel therapies, although it navigates a competitive and risky landscape typical of biotech firms.

Competitive Landscape

Opportunities & Challenges

Industry Position

Synlogic holds a unique position within the biopharmaceutical industry, focusing on synthetic biology to create novel therapies. Key aspects of its industry standing include:

• Innovative Technology: Synlogic's therapeutic platform is built on the principles of synthetic biology, differentiating it from traditional pharmaceutical approaches.
• Niche Market Focus: The company targets specific metabolic and immunological diseases, allowing it to concentrate its resources and expertise.
• Collaborative Approach: Synlogic actively seeks collaborations with other companies and research institutions to advance its programs.

To gain more insights into investor behavior and company performance, check out this link: Exploring Synlogic, Inc. (SYBX) Investor Profile: Who’s Buying and Why?